Urologic oncology · 2025
Inflammatory bowel disease vs. adverse in-hospital outcomes after radical prostatectomy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Catanzaro Calogero, Peñaranda Natali Rodriguez, Marmiroli Andrea, Longoni Mattia, Le Quynh Chi, Falkenbach Fabian, Nicolazzini Michele, Goyal Jordan A, Bianchi Lorenzo, Piazza Pietro, Mottaran Angelo, Saad Fred, Shariat Shahrokh F, Micali Salvatore, Musi Gennaro, Briganti Alberto, Chun Felix K H, Graefen Markus, Volpe Alessandro, Schiavina Riccardo, Karakiewicz Pierre I
Аннотация
INTRODUCTION: The effect of inflammatory bowel disease (IBD) on adverse in-hospital outcomes after radical prostatectomy (RP) for nonmetastatic prostate cancer (PCa) is not well known.
MATERIALS AND METHODS: Descriptive analyses, propensity score matching and multivariable logistic regression models were used within the National Inpatient Sample (2000-2019) RP patients, after stratification according to Crohn's disease (CD) vs. ulcerative colitis (UC) vs. no-IBD, and RP type (minimally invasive [MIRP] vs. open [ORP]).
RESULTS: Of 251,334 RP patients, 486 (0.2%) had CD vs. 446 (0.2%) UC. In CD patients vs. no-IBD counterparts, MIRP (n = 223) independently predicted higher rates of adverse in-hospital outcomes in 3/15 categories, including overall (OR:1.64, P < 0.01) and postoperative (OR:1.73, P < 0.01) complications. Conversely, in CD patients vs. no-IBD counterparts, ORP (n = 263) independently predicted higher rates of adverse in-hospital outcomes in 5/15 categories, including also overall (OR:1.37, P < 0.05), and postoperative (OR:1.44, P < 0.05) complications. In UC patients vs. no-IBD counterparts, MIRP (n = 218) independently predicted higher rates of adverse in-hospital outcomes in only 1/15 categories, namely prolonged length of stay (OR:1.64, P < 0.001). Conversely, in UC patients vs. no-IBD counterparts, ORP (n = 228) independently predicted higher rates of adverse in-hospital outcomes in 3/15 categories, including overall (OR:1.49, P < 0.05) and intraoperative (OR:2.31, P < 0.01) complications.
CONCLUSION: In the current analysis, direct comparisons with no-IBD patients showed worse in-hospital outcomes for both CD and UC patients, with adverse in-hospital outcomes indirectly appearing more severe in CD than in UC patients. In both subgroups, MIRP was associated with fewer adverse outcomes than ORP, based on comparison with no-IBD patients.
MATERIALS AND METHODS: Descriptive analyses, propensity score matching and multivariable logistic regression models were used within the National Inpatient Sample (2000-2019) RP patients, after stratification according to Crohn's disease (CD) vs. ulcerative colitis (UC) vs. no-IBD, and RP type (minimally invasive [MIRP] vs. open [ORP]).
RESULTS: Of 251,334 RP patients, 486 (0.2%) had CD vs. 446 (0.2%) UC. In CD patients vs. no-IBD counterparts, MIRP (n = 223) independently predicted higher rates of adverse in-hospital outcomes in 3/15 categories, including overall (OR:1.64, P < 0.01) and postoperative (OR:1.73, P < 0.01) complications. Conversely, in CD patients vs. no-IBD counterparts, ORP (n = 263) independently predicted higher rates of adverse in-hospital outcomes in 5/15 categories, including also overall (OR:1.37, P < 0.05), and postoperative (OR:1.44, P < 0.05) complications. In UC patients vs. no-IBD counterparts, MIRP (n = 218) independently predicted higher rates of adverse in-hospital outcomes in only 1/15 categories, namely prolonged length of stay (OR:1.64, P < 0.001). Conversely, in UC patients vs. no-IBD counterparts, ORP (n = 228) independently predicted higher rates of adverse in-hospital outcomes in 3/15 categories, including overall (OR:1.49, P < 0.05) and intraoperative (OR:2.31, P < 0.01) complications.
CONCLUSION: In the current analysis, direct comparisons with no-IBD patients showed worse in-hospital outcomes for both CD and UC patients, with adverse in-hospital outcomes indirectly appearing more severe in CD than in UC patients. In both subgroups, MIRP was associated with fewer adverse outcomes than ORP, based on comparison with no-IBD patients.